Nurse Practitioner in Twisp, WA Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Blue E Bradley, CNM, ARNP Nurse Practitioner - Women's Health Medicare: Accepting Medicare Assignments Practice Location: 541 W. Second Avenue, Twisp, WA 98856 Phone: 509-422-5700 |
Ms. Charlene Ann Burns, ARNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 82 Finley Canyon Rd, Twisp, WA 98856 Phone: 509-997-0818 |
Kathleen Mary Manseau, A.R.N.P. Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 541 W. Second Avenue, Twisp, WA 98856 Phone: 509-422-5700 Fax: 509-422-7680 |
News Archive
Screening for atrial fibrillation in the elderly could help avoid stroke and death
Screening for atrial fibrillation in 75- and 76-year-olds could reduce the risk of stroke, severe bleeding and death, according to a study at Karolinska Institutet in Sweden that has been published in the journal The Lancet.
Duke-NUS researchers highlight possible role of bioaerosol sampling in pandemic surveillance
As a leading global city with a high population density, Singapore is vulnerable to the introduction of biological threats. Initiating an early emergency response to such threats calls for the rapid identification of the causative agent.
Medical device to reduce frequency of seizures in epilepsy patients gets FDA approval
The U.S. Food and Drug Administration today approved a device to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications.
Research: Tumor-suppressing protein linked with CHARGE syndrome
CHARGE, which affects 1 in 10,000 babies, is an acronym whose letters stand for some of the more common symptoms of the condition: coloboma of the eye, heart defects, atresia of the choanae, retardation of growth and/or development, genital and/or urinary abnormalities, and ear abnormalities and deafness.
Arius begins toxicology program for lead anti-cancer antibody
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
› Verified 3 days ago